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Letter to the Editor    
    
Tolperisone hel and the quality of life of 
neurolathyrism patients in rural Ethiopia    
    
Dear Editor,   
    
   
Neurolathysism (NL) is a central motor 
disorder caused by excessive and prolonged 
consumption of the grass pea, Lathyrus sativus 
which contains the glutamate analogue 
excitatoxin ß-N=oxalyl=a, ß- 
Diaminopropionic acid (1).  It also exists in a 
form of epidemics during times of food 
shortages as in flooding and famine primarily 
affecting the poor deprived farming 
communities (2,3).  The disease is endemic in 
Ethiopia and the Indian sub-continent. 
   There is no established mode of treatment for 
Neurolathyrism.  But the central muscle 
relaxant Tolperisone Hcl (Mydocalm: 
Chemical name=2, 4-dietyl- 3- 
piperidinopropriophenone, Gedeon Richter, 
Budapest, Hungary) was reported to be 
effective in alleviating the symptoms of NL in 
Bangladesh (4) and Ethiopia (5).  But there was 
no report about the impact of the drug on the 
life of the patients who are hard-pressed to lead 
a very difficult life without any medical and 
rehabilitative service.  And hence we have 
investigated some effects of the drug on the life 
quality of life of the patients and recorded their 
perspective. 
   The study was conducted between January 
and March 1996 in the rural Estie health centre 
of South Gondar, Northern Ethiopia.  A 
questionnaire was employed to collect baseline 
information and to follow patients for 
subjective and objective assessment. 
   A total of 16 patients were randomly selected 
and included in the study and followed for 12 
weeks receiving Tolperisone HCI 150 mg per 
so twice daily with a weekly follow up at the 
health centre.  Fourteen (87.5%) were males 
and 2(12.5%) were females.  The mean age was 
18.5 years (Range=13-50).  The classification 
system of NL after Acton modified by Tejke 
Gaunabit was used to categories patients 
according to their disability (2).  Six patients 
each were in Stage I (no stick) and Stage II (one 
stick).  Four patients were in Stage III (two 
sticks).  Patients in Stage IV (crawler) were not 
included in the study. 
   It was found that muscle ache, heaviness of 
legs, flexor spasm and repeated falling 
accidents showed significant improvement in 
majority (75%) of patients by the end of 8th 
week of treatment. When the need for support 
is considered, four patients who used one 
supporting cane (stage II) have virtually left 
their stich at the end of the treatment.  Likewise 
one patient in stage III (two stick) left one of 
the sticks.  All the patients in stage I and half in 
Stage II (56% of the total) reported to take 
newer farming tasks with in eight weeks of the 
treatment. 
   Overall assessment 14 (87.5%) of patients 
disclosed to have a very good improvement in 
their disability after the treatment.  Muscle 
power, sustained ankle clonus and adductor 
stiffness were improved or absent in all the 
patients by the end of the study.  Walking 
ability was very much improved in 87.5% of 
patients at the study.  No patient discontinued 
the drug for side effects. 
   Fifteen of the 16 patients were interviewed 
and examined 12 months after the study.  By 
then it was only in 40% of the patients that had 
muscle ache, flexor spasms and heaviness of 
legs remained improved after the treatment.  
All the patients who left their supporting cane 
while on Toperisone started to use it again few 
weeks after the cessation of the drug.  All the 
patients were willing to continue the drug for 
its benefits even one year after the study.  
   Our conclusion is that Telperisone Hcl in a 
maintenance dose of 150 mg per os twice daily 
is tolerable in the symptomatic treatment of NL 
and improveving the physical disability of 
patients in the earlier stages of the disease. 
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